留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

植入药物洗脱支架后短期与长期双联抗血小板疗效比较的Meta分析

费舒扬,  赵力,  孙琳,  张蓉,  李晶,  葛长江

downloadPDF
文章导航 > 药学实践与服务  > 2020 >  38(1): 81-87
费舒扬, 赵力, 孙琳, 张蓉, 李晶, 葛长江. 植入药物洗脱支架后短期与长期双联抗血小板疗效比较的Meta分析[J]. 药学实践与服务, 2020, 38(1): 81-87. doi: 10.3969/j.issn.1006-0111.201907135
引用本文: 费舒扬, 赵力, 孙琳, 张蓉, 李晶, 葛长江. 植入药物洗脱支架后短期与长期双联抗血小板疗效比较的Meta分析[J]. 药学实践与服务, 2020, 38(1): 81-87. doi: 10.3969/j.issn.1006-0111.201907135
shu
FEI Shuyang, ZHAO Li, SUN Lin, ZHANG Rong, LI Jing, GE Changjiang. Comparison of short-term and long-term dual antiplatelet therapy after implantation of drug-eluting stents—Meta analysis[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 81-87. doi: 10.3969/j.issn.1006-0111.201907135
Citation: FEI Shuyang, ZHAO Li, SUN Lin, ZHANG Rong, LI Jing, GE Changjiang. Comparison of short-term and long-term dual antiplatelet therapy after implantation of drug-eluting stents—Meta analysis[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 81-87. doi: 10.3969/j.issn.1006-0111.201907135
shu

植入药物洗脱支架后短期与长期双联抗血小板疗效比较的Meta分析

doi: 10.3969/j.issn.1006-0111.201907135
  • 1.

    首都医科大学附属北京安贞医院, 北京 100048

  • 2.

    解放军总医院第六医学中心, 北京 100048

Comparison of short-term and long-term dual antiplatelet therapy after implantation of drug-eluting stents—Meta analysis

  • 1.

    Anzhen Hospital, Capital Medical University, Beijing 100048, China

  • 2.

    Sixth Medical Center of General Hospital of PLA, Beijing 100048, China

  • 摘要: 目的 评价短期（3～6个月）与长期（12个月）双联抗血小板治疗对冠状动脉药物洗脱支架植入后的临床效果。 方法 研究病例包括稳定性心绞痛、急性冠脉综合征、无症状心肌缺血，均为原位血管病变。临床观察终点为：全因死亡、心源性死亡、心肌梗死、卒中、支架内血栓形成、靶病变再血管化治疗、严重出血、净不良临床事件（net adverse clinical event）。通过检索Pubmed、中国生物医学文献等中、英文数据库及手工检索，对符合条件的随机对照研究经质量评估、数据提取，进行Meta分析。 结果 共计纳入12项随机对照研究。Detsky评分均大于5分。共计25 949个病例，随访率97.9%。两组在全因死亡（OR=0.86，95%CI 0.71～1.05，P=0.14）、心源性死亡（OR=0.94，95% CI 0.70～1.25，P=0.67）、支架血栓形成（OR=1.36，95%CI 0.94～1.98，P=0.11）、卒中（OR=1.01，95%CI 0.71～1.42，P=0.98）、靶病变再血管化（OR=0.121，95%CI 0.94～1.55，P=0.14）及净不良临床事件（OR=0.98，95%CI 0.83～1.14，P=0.75）均无明显差别；短期组随访期间心肌梗死发生率高于长期组（OR=1.27，95%CI 1.02～1.59，P=0.04），长期组严重出血的比例明显增加（OR=0.69，95%CI 0.50～0.95，P=0.02）。亚洲人群研究结果：长期治疗组全因死亡高于短期组（OR=0.72，95%CI 0.53～0.97，P=0.03），两组严重出血无明显差别。 结论 依据限定的临床观察终点，短期双联抗血小板疗效不劣于长期组；7项亚组人群研究，长期组全因死亡率高，不排除与样本量偏少产生的偏移及（或）人群的个体差异有关，结果还有待进一步验证。此结果可作为临床工作警示，依据患者出血风险及冠状动脉病变结果个体化调整双联抗血小板周期。
    Abstract: Objective To evaluate the clinical effects of short-term (3-6 months) and long-term (12 months) dual antiplatelet therapy (DAPT) after the implantation of coronary drug-eluting stents (DES). Methods The eligibilities of the patients included stable angina, acute coronary syndrome and silent ischemia. The lesions were in a native coronary vessel. The clinical observation endpoints were all-cause death, cardiogenic death, myocardial infarction, stroke, stent thrombosis, target lesion revascularization, severe bleeding, and true adverse clinical events. The clinical observation endpoints were all-cause death, cardiogenic death, myocardial infarction, stroke, stent thrombosis, target lesion revascularization, severe bleeding, and true adverse clinical events. By searching Pubmed, Chinese biomedical literature and other Chinese and English databases and manual search, qualified randomized controlled studies were evaluated and data were extracted for meta-analysis. Results A total of 12 randomized controlled studies were conducted. Detsky scores were all greater than 5 points. There were a total of 25949 patients in the study with a follow-up rate of 97.9%. There were no significantly different in all cause death (OR=0.86,95%CI 0.71-1.05,P=0.14), cardiac death (OR=0.94,95% CI 0.70-1.25,P=0.67), stent thrombosis (OR=1.36,95%CI 0.94-1.98,P=0.11), stroke (OR=1.01,95%CI 0.71-1.42,P=0.98), target lesion revascularization (OR=0.121,95%CI 0.94-1.55,P=0.14),and true adverse clinical events (OR=0.98,95%CI 0.83-1.14,P=0.75). The incident rate of myocardial infarction during the follow-up period was higher in the short-term group than in the long-term group (OR=1.27, 95% CI 1.02-1.59, P=0.04). The proportion of severe bleeding in the long-term group increased significantly (OR=0.69, 95% CI 0.50-0.95, P=0.02). Asian population studies showed that all-cause mortality was higher in the long-term treatment group than in the short-term group (OR=0.72, 95% CI 0.53-0.97, P=0.03), and there was no significant difference in severe bleeding between the two groups. Conclusion According to the defined clinical observation endpoints, the short-term dual antiplatelet effect is not inferior to the long-term group. Seven asian group studies have shown that the long-term group has high all-cause mortality. It can not rule out the deviation and/or population caused by the small sample size or individual variation. The results need to be further verified. This result can be used as a clinical warning to adjust the dual antiplatelet cycle based on the individualized risk of bleeding and coronary lesions.
  • [1] BYRNE R A, SARAFOFF N, KASTRATI A, et al. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment[J]. Drug Saf,2009,32(9):749-770
    [2] VALGIMIGLI M, BUENO H, BYRNE R A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS[J]. Eur J Cardiothorac Surg,2018,53(1):34-78
    [3] LEVINE G N, BATES E R, BITTL J A, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American college of cardiology/ American heart association task force on clinical practice guidelines[J]. J Am Coll Cardiol,2016,68(10):1082-1115
    [4] BONACA M P, BHATT D L, COHEN M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med,2015,372(19):1791-1800
    [5] YEH R W, SECEMSKY E A, KEREIAKES D J, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention[J]. JAMA,2016,315(16):1735-1749
    [6] BABER U, MEHRAN R, GIUSTINO G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from Paris[J]. J Am Coll Cardiol,2016,67(19):2224-2234
    [7] GRANGER C B, GOLDBERG R J, DABBOUS O, et al. Predictors of hospital mortality in the global registry of acute coronary events[J]. Arch Intern Med,2003,163(19):2345-2353
    [8] MEHRAN R, POCOCK S J, NIKOLSKY E, et al. A risk score to predict bleeding in patients with acute coronary syndromes[J]. J Am Coll Cardiol,2010,55(23):2556-2566
    [9] DETSKY A S, NAYLOR C D, O'ROURKE K, et al. Incorporating variations in the quality of individual randomized trials into meta-analysis[J]. J Clin Epidemiol,1992,45(3):255-265
    [10] GWON H C, HAHN J Y, PARK K W, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study[J]. Circulation,2012,125(3):505-513
    [11] KIM B K, HONG M K, SHIN D H, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (Real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation)[J]. J Am Coll Cardiol,2012,60(15):1340-1348
    [12] FERES F, COSTA R A, ABIZAID A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial[J]. JAMA,2013,310(23):2510-2522
    [13] COLOMBO A, CHIEFFO A, FRASHERI A, et al. Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial[J]. J Am Coll Cardiol,2014,64(20):2086-2097
    [14] GILARD M, BARRAGAN P, NORYANI A A L, et al. 6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial[J]. J Am Coll Cardiol,2015,65(8):777-786
    [15] SCHULZ-SCHUPKE S, BYRNE R A, TEN BERG J M, et al. Intracoronary stenting and antithrombotic regimen: safety and efficacy of 6 months dual antiplatelet therapy after drug-eluting stenting (ISAR-SAFE) trial investigators. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting[J]. Eur Heart J,2015,36:1252-1263
    [16] HONG S J, SHIN D H, KIM J S, et al. 6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial[J]. JACC Cardiovasc Interv,2016,9(14):1438-1446
    [17] HAN Y L, XU B, XU K, et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial[J]. Circ Cardiovasc Interv,2016,9(2):e003145
    [18] NAKAMURA M, ⅡJIMA R, AKO J, et al. Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation[J]. JACC Cardiovasc Interv,2017,10(12):1189-1198
    [19] LEE B K, KIM J S, LEE O H, et al. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy[J]. EuroIntervention,2018,13(16):1923-1930
    [20] HAHN J Y, SONG Y B, OH J H, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial[J]. Lancet,2018,391(10127):1274-1284
    [21] KEDHI E, FABRIS E, VAN DER ENT M, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial[J]. BMJ,2018:k3793
    [22] VALGIMIGLI M, CAMPO G, MONTI M, et al. Prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study (PRODIGY) investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial[J]. Circulation,2012,125:2015-2026
    [23] MAURI L, KEREIAKES D J, YEH R W, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents[J]. N Engl J Med,2014,371(23):2155-2166
    [24] COLLET J P, SILVAIN J, BARTHÉLÉMY O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial[J]. Lancet,2014,384(9954):1577-1585
    [25] LEE C W, AHN J M, PARK D W, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial[J]. Circulation,2014,129(3):304-312
    [26] PARK S J, PARK D W, KIM Y H, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents[J]. N Engl J Med,2010,362(15):1374-1382
    [27] GARRATT K N, WEAVER W D, JENKINS R G, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after Taxus Liberté paclitaxel-eluting coronary stent placement[J]. Circulation,2015,131(1):62-73
    [28] COSTA F, VRANCKX P, LEONARDI S, et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging dual-antiplatelet treatment after grading stent-induced intimal hyperplasia) trial[J]. Eur Heart J,2015,36(20):1242-1251
    [29] SABATÉ M, RÄBER L, HEG D, et al. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical evaluation of the xience-V stent in acute myocardial infarction) and COMFORTABLE-AMI (comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction) trials[J]. JACC Cardiovasc Interv,2014,7(1):55-63
    [30] 中华医学会心血管病学. 2013年抗血小板治疗中国专家共识[J]. 中华心血病杂志, 2013, 40(3):183-194
  • [1] 李锐, 张倩倩, 王瑞冬, 高小峰.  国家集中带量采购政策下样本医院良性前列腺增生治疗药物使用情况分析 . 药学实践与服务, 2025, 43(2): 1-6. doi: 10.12206/j.issn.2097-2024.202408031
    [2] 郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛.  醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202310043
    [3] 宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦.  脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
    [4] 白学鑫, 陈玉平, 盛春泉, 武善超.  具核梭杆菌小分子抑制剂的筛选及其抗结直肠癌活性研究 . 药学实践与服务, 2024, 42(12): 503-507. doi: 10.12206/j.issn.2097-2024.202405009
    [5] 宋泽成, 马闪闪, 胡巧灵, 仲华, 王彦.  小檗碱与氟康唑合用抗白念珠菌耐受菌的研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202409047
    [6] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
    [7] 何亚伦, 祁智, 常杰.  消胀通便膏在晚期肝癌患者阿片类药物相关性便秘中的应用研究 . 药学实践与服务, 2024, 42(12): 520-523. doi: 10.12206/j.issn.2097-2024.202309009
    [8] 石晓萍, 吕迁洲, 李晓宇, 许青.  泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050
    [9] 孙丹倪, 黄勇, 张嘉宝, 王培.  代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
    [10] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [11] 关梦瑶, 夏天爽, 何旭辉, 蒋益萍, 辛海量.  黑蒜多糖抗便秘作用研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202403059
    [12] 张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫.  基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
    [13] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [14] 迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛.  负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
    [15] 舒飞, 孙蕊, 宋凯, 张元林, 闫家铭, 舒丽芯.  粉-液双室袋产品综合评估 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202312009
    [16] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [17] 张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一.  药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
    [18] 王鹏, 陈顺, 赵逸, 高守红, 王志鹏.  卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(9): 385-388, 398. doi: 10.12206/j.issn.2097-2024.202308045
    [19] 丁千雪, 尚圣兰, 余梦辰, 余爱荣.  机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
    [20] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  5015
  • HTML全文浏览量:  572
  • PDF下载量:  2896
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-07-29
  • 修回日期:  2019-12-25

植入药物洗脱支架后短期与长期双联抗血小板疗效比较的Meta分析

doi: 10.3969/j.issn.1006-0111.201907135
  • 1. 首都医科大学附属北京安贞医院, 北京 100048
  • 2. 解放军总医院第六医学中心, 北京 100048
  • 收稿日期: 2019-07-29
  • 修回日期: 2019-12-25

摘要: 目的 评价短期（3～6个月）与长期（12个月）双联抗血小板治疗对冠状动脉药物洗脱支架植入后的临床效果。 方法 研究病例包括稳定性心绞痛、急性冠脉综合征、无症状心肌缺血，均为原位血管病变。临床观察终点为：全因死亡、心源性死亡、心肌梗死、卒中、支架内血栓形成、靶病变再血管化治疗、严重出血、净不良临床事件（net adverse clinical event）。通过检索Pubmed、中国生物医学文献等中、英文数据库及手工检索，对符合条件的随机对照研究经质量评估、数据提取，进行Meta分析。 结果 共计纳入12项随机对照研究。Detsky评分均大于5分。共计25 949个病例，随访率97.9%。两组在全因死亡（OR=0.86，95%CI 0.71～1.05，P=0.14）、心源性死亡（OR=0.94，95% CI 0.70～1.25，P=0.67）、支架血栓形成（OR=1.36，95%CI 0.94～1.98，P=0.11）、卒中（OR=1.01，95%CI 0.71～1.42，P=0.98）、靶病变再血管化（OR=0.121，95%CI 0.94～1.55，P=0.14）及净不良临床事件（OR=0.98，95%CI 0.83～1.14，P=0.75）均无明显差别；短期组随访期间心肌梗死发生率高于长期组（OR=1.27，95%CI 1.02～1.59，P=0.04），长期组严重出血的比例明显增加（OR=0.69，95%CI 0.50～0.95，P=0.02）。亚洲人群研究结果：长期治疗组全因死亡高于短期组（OR=0.72，95%CI 0.53～0.97，P=0.03），两组严重出血无明显差别。 结论 依据限定的临床观察终点，短期双联抗血小板疗效不劣于长期组；7项亚组人群研究，长期组全因死亡率高，不排除与样本量偏少产生的偏移及（或）人群的个体差异有关，结果还有待进一步验证。此结果可作为临床工作警示，依据患者出血风险及冠状动脉病变结果个体化调整双联抗血小板周期。

English Abstract

费舒扬, 赵力, 孙琳, 张蓉, 李晶, 葛长江. 植入药物洗脱支架后短期与长期双联抗血小板疗效比较的Meta分析[J]. 药学实践与服务, 2020, 38(1): 81-87. doi: 10.3969/j.issn.1006-0111.201907135
引用本文: 费舒扬, 赵力, 孙琳, 张蓉, 李晶, 葛长江. 植入药物洗脱支架后短期与长期双联抗血小板疗效比较的Meta分析[J]. 药学实践与服务, 2020, 38(1): 81-87. doi: 10.3969/j.issn.1006-0111.201907135
shu
FEI Shuyang, ZHAO Li, SUN Lin, ZHANG Rong, LI Jing, GE Changjiang. Comparison of short-term and long-term dual antiplatelet therapy after implantation of drug-eluting stents—Meta analysis[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 81-87. doi: 10.3969/j.issn.1006-0111.201907135
Citation: FEI Shuyang, ZHAO Li, SUN Lin, ZHANG Rong, LI Jing, GE Changjiang. Comparison of short-term and long-term dual antiplatelet therapy after implantation of drug-eluting stents—Meta analysis[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 81-87. doi: 10.3969/j.issn.1006-0111.201907135
shu

    全文HTML

参考文献 (30)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计